Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2005 Feb;60(2):120–123. doi: 10.1136/thx.2004.030239

Efficacy of bupropion in the indigenous Maori population in New Zealand

S Holt 1, C Timu-Parata 1, S Ryder-Lewis 1, M Weatherall 1, R Beasley 1
PMCID: PMC1747282  PMID: 15681499

Abstract

Background: Smoking rates are high in indigenous populations and contribute to their poor health. In New Zealand the indigenous Maori population has a high rate of smoking, with around 50% of adults being smokers compared with 20% of the adult European population. A study was undertaken to determine whether bupropion is effective in the treatment of smoking cessation in the indigenous Maori population in New Zealand.

Methods: A randomised, placebo controlled, double blind, parallel group study was performed in 134 Maori smokers aged 16–70 years who smoked more than 10 cigarettes per day. The main outcome measures were continued abstinence from smoking at 3 and 12 months.

Results: At each time point continued abstinence was better for the subjects allocated to bupropion, with a risk ratio for abstinence over all time points of 2.44 (95% CI 1.22 to 4.88). The rates of continued abstinence in the bupropion and placebo groups at 3 months were 44.3% and 17.4%, respectively, with a risk ratio of 2.54 (95% CI 1.30 to 5.00). The corresponding figures at 12 months were 21.6% and 10.9%, respectively, with a risk ratio of 1.99 (95% CI 0.79 to 5.00).

Conclusion: Bupropion is an effective treatment for smoking cessation in the indigenous Maori population in New Zealand.

Full Text

The Full Text of this article is available as a PDF (93.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia Jasjit S., Harris Kari Jo, Catley Delwyn, Okuyemi Kolawole S., Mayo Matthew S. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA. 2002 Jul 24;288(4):468–474. doi: 10.1001/jama.288.4.468. [DOI] [PubMed] [Google Scholar]
  2. Borman B., Wilson N., Mailing C. Socio-demographic characteristics of New Zealand smokers: results from the 1996 census. N Z Med J. 1999 Dec 10;112(1101):460–463. [PubMed] [Google Scholar]
  3. Campbell M. J., Julious S. A., Altman D. G. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995 Oct 28;311(7013):1145–1148. doi: 10.1136/bmj.311.7013.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dale L. C., Hurt R. D., Hays J. T. Drug therapy to aid in smoking cessation. Tips on maximizing patients' chances for success. Postgrad Med. 1998 Dec;104(6):75-8, 83-4. doi: 10.3810/pgm.1998.12.390. [DOI] [PubMed] [Google Scholar]
  5. Durie Mason H. The health of indigenous peoples. BMJ. 2003 Mar 8;326(7388):510–511. doi: 10.1136/bmj.326.7388.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hays J. T., Hurt R. D., Rigotti N. A., Niaura R., Gonzales D., Durcan M. J., Sachs D. P., Wolter T. D., Buist A. S., Johnston J. A. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med. 2001 Sep 18;135(6):423–433. doi: 10.7326/0003-4819-135-6-200109180-00011. [DOI] [PubMed] [Google Scholar]
  7. Holm K. J., Spencer C. M. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000 Apr;59(4):1007–1024. doi: 10.2165/00003495-200059040-00019. [DOI] [PubMed] [Google Scholar]
  8. Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C., Khayrallah M. A., Schroeder D. R., Glover P. N., Sullivan C. R. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997 Oct 23;337(17):1195–1202. doi: 10.1056/NEJM199710233371703. [DOI] [PubMed] [Google Scholar]
  9. Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R., Smith S. S., Muramoto M. L., Daughton D. M., Doan K. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 Mar 4;340(9):685–691. doi: 10.1056/NEJM199903043400903. [DOI] [PubMed] [Google Scholar]
  10. Kane K. Y., Ellis M. R. Bupropion or patch for smoking cessation? J Fam Pract. 1999 Jun;48(6):419–419. [PubMed] [Google Scholar]
  11. Klemp P., Robertson M. C., Stansfield S., Klemp J. A., Harding E. Factors associated with smoking and the reasons for stopping in Maori and Europeans: a comparative study. N Z Med J. 1998 Apr 24;111(1064):148–501. [PubMed] [Google Scholar]
  12. McPherson K. M., Harwood M., McNaughton H. K. Ethnicity, equity, and quality: lessons from New Zealand. BMJ. 2003 Aug 23;327(7412):443–444. doi: 10.1136/bmj.327.7412.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Molyneux Andrew. Nicotine replacement therapy. BMJ. 2004 Feb 21;328(7437):454–456. doi: 10.1136/bmj.328.7437.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Richmond Robyn, Zwar Nicholas. Review of bupropion for smoking cessation. Drug Alcohol Rev. 2003 Jun;22(2):203–220. doi: 10.1080/09595230100100642. [DOI] [PubMed] [Google Scholar]
  15. Ring Ian, Brown Ngiare. The health status of indigenous peoples and others. BMJ. 2003 Aug 23;327(7412):404–405. doi: 10.1136/bmj.327.7412.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Roddy Elin. Bupropion and other non-nicotine pharmacotherapies. BMJ. 2004 Feb 28;328(7438):509–511. doi: 10.1136/bmj.328.7438.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tashkin D., Kanner R., Bailey W., Buist S., Anderson P., Nides M., Gonzales D., Dozier G., Patel M. K., Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001 May 19;357(9268):1571–1575. doi: 10.1016/s0140-6736(00)04724-3. [DOI] [PubMed] [Google Scholar]
  18. Tonstad S., Farsang C., Klaene G., Lewis K., Manolis A., Perruchoud A. P., Silagy C., van Spiegel P. I., Astbury C., Hider A. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003 May;24(10):946–955. doi: 10.1016/s0195-668x(03)00003-4. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES